Waldmeier P - Search Results

1

A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.

Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S. Chopra V, et al. Among authors: waldmeier p. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16685-9. doi: 10.1073/pnas.0707842104. Epub 2007 Oct 9. Proc Natl Acad Sci U S A. 2007. PMID: 17925440 Free PMC article.

2

Protective effects of NIM811 in transient focal cerebral ischemia suggest involvement of the mitochondrial permeability transition.

Korde AS, Pettigrew LC, Craddock SD, Pocernich CB, Waldmeier PC, Maragos WF. Korde AS, et al. Among authors: waldmeier pc. J Neurotrauma. 2007 May;24(5):895-908. doi: 10.1089/neu.2006.0122. J Neurotrauma. 2007. PMID: 17518543

3

Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death?

Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Sullivan PG, et al. Among authors: waldmeier pc. J Neurosci Res. 2005 Jan 1-15;79(1-2):231-9. doi: 10.1002/jnr.20292. J Neurosci Res. 2005. PMID: 15573402 Review.

4

The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria.

Hansson MJ, Mattiasson G, Månsson R, Karlsson J, Keep MF, Waldmeier P, Ruegg UT, Dumont JM, Besseghir K, Elmér E. Hansson MJ, et al. Among authors: waldmeier p. J Bioenerg Biomembr. 2004 Aug;36(4):407-13. doi: 10.1023/B:JOBB.0000041776.31885.45. J Bioenerg Biomembr. 2004. PMID: 15377880

5

An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease.

Sagot Y, Toni N, Perrelet D, Lurot S, King B, Rixner H, Mattenberger L, Waldmeier PC, Kato AC. Sagot Y, et al. Among authors: waldmeier pc. Br J Pharmacol. 2000 Oct;131(4):721-8. doi: 10.1038/sj.bjp.0703633. Br J Pharmacol. 2000. PMID: 11030721 Free PMC article.

6

Neurorescuing effects of the GAPDH ligand CGP 3466B.

Waldmeier PC, Boulton AA, Cools AR, Kato AC, Tatton WG. Waldmeier PC, et al. J Neural Transm Suppl. 2000;(60):197-214. doi: 10.1007/978-3-7091-6301-6_13. J Neural Transm Suppl. 2000. PMID: 11205140

7

CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.

Waldmeier PC, Spooren WP, Hengerer B. Waldmeier PC, et al. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):526-37. doi: 10.1007/s002100000300. Naunyn Schmiedebergs Arch Pharmacol. 2000. PMID: 11138845

8

GABA and glutamate release affected by GABAB receptor antagonists with similar potency: no evidence for pharmacologically different presynaptic receptors.

Waldmeier PC, Wicki P, Feldtrauer JJ, Mickel SJ, Bittiger H, Baumann PA. Waldmeier PC, et al. Br J Pharmacol. 1994 Dec;113(4):1515-21. doi: 10.1111/j.1476-5381.1994.tb17168.x. Br J Pharmacol. 1994. PMID: 7889310 Free PMC article.

9

Determination of rat brain and plasma levels of the orally active GABAB antagonist 3-amino-propyl-n-butyl-phosphinic acid (CGP 36742) by a new GC/MS method.

Steulet AF, Mobius HJ, Mickel SJ, Stocklin K, Waldmeier PC. Steulet AF, et al. Among authors: waldmeier pc. Biochem Pharmacol. 1996 Mar 8;51(5):613-9. doi: 10.1016/s0006-2952(95)02183-3. Biochem Pharmacol. 1996. PMID: 8615897

10

Displacement of in vivo binding of [3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine.

Waldmeier PC, Stöcklin K. Waldmeier PC, et al. Eur J Pharmacol. 1992 Jun 5;216(2):243-7. doi: 10.1016/0014-2999(92)90366-c. Eur J Pharmacol. 1992. PMID: 1397011

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146 results

Search Page

Filters